Novo Nordisk A/S ADR (NVO) News
Filter NVO News Items
NVO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NVO News From Around the Web
Below are the latest news stories about NOVO NORDISK A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. |
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded DealFDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels. |
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock. |
Novo, Eli Lilly to dominate global pharma sales in 2025: reportMore on Eli Lilly, Merck, etc. |
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep ApneaPopular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month. |
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyNovo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy. |
LLY Falls Around 14% in 3 Months: How to Play the StockThough Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects. |
Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory?Eli Lilly stock is trading below its key moving averages, but Zepbound just won a new approval. Is LLY stock now a buy? |
5 questions facing pharma in 2025Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out. |
Novo Nordisk and Valo expand cardiometabolic drug partnershipThe collaboration includes 20 drug programmes and could yield up to $4.6bn in milestone payments for Valo. |